Your browser doesn't support javascript.
loading
Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer.
Chu, Yu-Yi; Yam, Clinton; Chen, Mei-Kuang; Chan, Li-Chuan; Xiao, Min; Wei, Yong-Kun; Yamaguchi, Hirohito; Lee, Pei-Chih; Han, Ye; Nie, Lei; Sun, Xian; Moulder, Stacy L; Hess, Kenneth R; Wang, Bin; Hsu, Jennifer L; Hortobagyi, Gabriel N; Litton, Jennifer; Chang, Jeffrey T; Hung, Mien-Chie.
Affiliation
  • Chu YY; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
  • Yam C; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
  • Chen MK; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
  • Chan LC; The University of Texas MD Anderson Cancer Center UT Health Graduate School of Biomedical Sciences Houston, TX 77030, USA.
  • Xiao M; This Research was Performed in Partial Fulfillment of The Requirements for The MS Degree From The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences; The University of Texas MD Anderson Cancer Center Houston, Texas 77030, USA.
  • Wei YK; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
  • Yamaguchi H; The University of Texas MD Anderson Cancer Center UT Health Graduate School of Biomedical Sciences Houston, TX 77030, USA.
  • Lee PC; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
  • Han Y; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
  • Nie L; Department of Breast Surgery, Harbin Medical University Cancer Hospital Harbin 150081, Heilongjiang, P. R. China.
  • Sun X; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
  • Moulder SL; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
  • Hess KR; Cancer Research Center, Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Qatar Foundation PO Box 34110, Doha, Qatar.
  • Wang B; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
  • Hsu JL; Graduate Institute of Biomedical Sciences, Research Center for Cancer Biology, Center for Molecular Medicine, China Medical University Taichung 404, Taiwan.
  • Hortobagyi GN; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
  • Litton J; Department of Second Breast Surgery, China Medical University Affiliated Shengjing Hospital Shenyang, P. R. China.
  • Chang JT; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
  • Hung MC; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Am J Cancer Res ; 10(2): 648-661, 2020.
Article in En | MEDLINE | ID: mdl-32195033
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Am J Cancer Res Year: 2020 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Am J Cancer Res Year: 2020 Type: Article Affiliation country: United States